Please assess the completion status of the following clinical trial:

Trial Title: Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Increased risk for ovarian cancer secondary to 1 of the following:~  * Evidence of a BRCA1 or BRCA2 genetic mutation~ * Family history of 1 or more first-degree relatives diagnosed with ovarian cancer prior to 50 years of age~ * Family history of 1 first-degree relative with ovarian cancer (any age) AND 1 or more first- or second-degree relatives diagnosed with breast or ovarian cancer~ * Personal history of breast cancer (at any age) AND 1 or more first- or second-degree relative diagnosed with breast or ovarian cancer at any age~* Meets any 1 of the following criteria:~  * Ashkenazi Jewish ethnicity with 1 first-degree or 2 second-degree relatives with breast\* and/or ovarian cancer~ * Ashkenazi Jewish ethnicity with diagnosed breast\* cancer in patient~ * Greater than 20% probability of carrying BRCA1/2 mutation with a family history of breast and ovarian cancer NOTE: \* Where breast cancer is required to meet this criteria, diagnosis must occur prior to menopause or at ≤ 50 years old if age at menopause is unknown~* Planned prophylactic oophorectomy~* Normal pelvic exam within the past 6 weeks~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* GOG 0-1~Life expectancy:~* At least 12 months~Hematopoietic:~* WBC at least 4,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* SGOT no greater than 2 times upper limit of normal (ULN)~Renal:~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance at least 60 mL/min~* Triglyceride less than 2 times ULN (fasting)~Cardiovascular:~* No myocardial infarction within the past 3 months~* No active angina~* No unstable heart rhythms~* No clinically evident congestive heart failure~Other:~* No uncontrolled medical illness that would preclude study participation~* No uncontrolled diabetes~* No uncontrolled psychiatric illness~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* At least 3 months since prior chemotherapy~Endocrine therapy:~* At least 3 months since prior hormonal therapy~* At least 8 weeks since prior hormone replacement therapy~* At least 8 weeks since prior oral, injectable, or implantable contraceptives~* No concurrent hormonal therapy, including hormone replacement therapy~Radiotherapy:~* At least 3 months since prior radiotherapy~* No prior radiotherapy to pelvis for malignancy~Surgery:~* See Disease Characteristics~Other:~* At least 3 months since prior investigational treatment~* No concurrent nutritional supplements except a daily multivitamin with less than 25,000 IU of vitamin A~* No prior non-steroidal anti-inflammatory drugs (NSAIDs) on a regular (chronic or daily) basis within the past 6 months~* No concurrent NSAIDs on a regular (chronic or daily) basis~* Concurrent aspirin at a dose of 81 mg/day allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues